abrdn Healthcare Investors Q1 2025 Commentary
Source: SeekingAlpha
2025-05-30 09:05:00 ET
Summary
- The equity portion of the Fund fell (gross of fees) and underperformed its benchmark over the quarter.
- During the first quarter of 2025, we made several changes to the portfolio.
- The top three detractors were Sarepta Therapeutics, Regeneron Pharmaceuticals and Vaxcyte.
- With Donald Trump securing his second term, uncertainty around election results has been replaced with policy ambiguity.
Fund performance
The equity portion of the Fund fell (gross of fees) and underperformed its benchmark over the quarter.[1]...
Read the full article on Seeking Alpha
For further details see:
abrdn Healthcare Investors Q1 2025 Commentary
Vaxcyte Inc.
NASDAQ: PCVX
PCVX Trading
-5.35% G/L:
$53.39 Last:
575,994 Volume:
$57.06 Open:
PCVX Latest News
February 24, 2026 04:05:00 pm
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
February 11, 2026 04:05:00 pm
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
February 10, 2026 04:05:00 pm
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
PCVX Stock Data
$7,801,730,421
136,657,209
0.01%
97
N/A
Biotechnology & Life Sciences
Healthcare
US
San Carlos
